Pfizer Reports Phase 3 Results for Sigvotatug Vedotin in NSCLC; No Overall Survival Benefit Observed
The Phase 3 SigVie-002 study of sigvotatug vedotin in previously treated metastatic NSCLC did not show a statistically significant improvement in overall survival compared to docetaxel, although a trend for better outcomes was noted in patients with only one prior therapy.